Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Still Not Comfortable With New Vaccine Adjuvants, Industry Veterans Say

Executive Summary

The wave of new adjuvant-boosted vaccines under development promises to protect new and broader populations against a host of previously elusive pathogens - including pandemic flu. However, until FDA has more experience with these novel combinations, the regulatory hurdles will remain high, speakers warned at the recent Immunotherapeutics & Vaccine Summit in Cambridge, Mass

You may also be interested in...



Therapeutic Cancer Vaccines Can Use Adjuvants, FDA Says

But even though the agency’s final guidance on cancer vaccines adds a section on adjuvants, the additional data requirements that FDA will request remain relatively vague.

Adjuvants Need Approval Pathway Separate From Vaccines, Industry Tells FDA

Industry is calling on FDA to write separate rules for assessing adjuvants. This would encourage innovation in immunotherapies, the Biotechnology Industry Organization and Pharmaceutical Research and Manufacturers of America contend.

Adjuvants Need Approval Pathway Separate From Vaccines, Industry Tells FDA

Industry is calling on FDA to write separate rules for assessing adjuvants. This would encourage innovation in immunotherapies, the Biotechnology Industry Organization and Pharmaceutical Research and Manufacturers of America contend.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052580

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel